EGFR and non-small cell lung carcinoma: In the presence of a sensitizing EGFR mutation, advanced NSCLC patients are treated frontline with selective tyrosine kinase inhibitors (TKI), among which gefitinib and erlotinib are first-generation TKIs, whereas afatinib and dacomitinib are second-generation irreversible inhibitors.